BLTE

Belite Bio, Inc

Price Chart

Latest Quote

$150.08

-0.59 (-0.39%)

Current Price

Previous Close	$150.67
Open	$150.78
Day High	$152.76
Day Low	$147.89
Volume	154,481

Fetched: 2026-07-18T06:45:11

Stock Information

Shares Outstanding	40.09M
Net Income	$-90.27M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$6.02B
EPS (TTM)	$-2.52
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Income	$-90.27M
Book/sh	$20.23
Employees	41

Financial Ratios

Current Ratio

33.71

Returns & Margins

ROA	-12.99%
ROE	-18.93%

Ownership

Insider Ownership	44.27%
Institutional Ownership	23.64%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	158.93
P/B	7.42

Analyst Data

Recommendation	none
Target Price	$210.50

Technical Indicators

SMA20	$149.78
SMA50	$146.62
SMA200	$146.07
RSI	51.32
ATR	7.4413

Shares Float	18.47M
Short Float	6.31%
Short Ratio	5.37
Volatility	-1.23
Rel Volume	0.77

Performance History

Week	+0.50%
Month	+8.60%
Quarter	-5.04%
6 Months	-2.34%
YTD	-5.77%
Year	+141.87%
3 Years	+1096.81%
10 Years	+1317.19%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-07-17	$150.08	155,000
2026-07-16	$150.67	116,300
2026-07-15	$149.47	102,800
2026-07-14	$146.68	107,900
2026-07-13	$147.03	194,600
2026-07-10	$149.33	153,700
2026-07-09	$153.24	124,000
2026-07-08	$152.30	311,900
2026-07-07	$157.69	222,500
2026-07-06	$154.02	214,300
2026-07-02	$146.63	109,400
2026-07-01	$142.31	354,100
2026-06-30	$153.99	225,100
2026-06-29	$154.65	195,300
2026-06-26	$148.73	255,700
2026-06-25	$149.83	270,700
2026-06-24	$150.77	275,300
2026-06-23	$145.09	214,900
2026-06-22	$147.07	172,400
2026-06-18	$146.12	255,100

About Belite Bio, Inc

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

📰 Latest News

Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease

MarketBeat • 2026-07-10T03:02:15Z

We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn

Simply Wall St. • 2026-06-12T18:45:56Z

Belite Bio Inc (BLTE) Q1 2026 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses

GuruFocus.com • 2026-05-21T05:00:52Z

Belite Bio Q1 Earnings Call Highlights

MarketBeat • 2026-05-20T22:06:19Z

Belite Bio (BLTE) Q1 2026 Earnings Transcript

Motley Fool • 2026-05-20T21:59:46Z

Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE)

InvestorsHub • 2026-05-20T10:57:17Z

Belite Bio (BLTE) Valuation Check As Tinlarebant Advances With Rolling FDA NDA Submission

Simply Wall St. • 2026-05-03T06:08:03Z

Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1

Insider Monkey • 2026-05-01T10:10:49Z

Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference

MarketBeat • 2026-04-28T15:29:07Z

How Belite Bio’s (BLTE) Rolling FDA NDA For Tinlarebant Has Changed Its Investment Story

Simply Wall St. • 2026-04-24T18:05:19Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$2,000	$20,000	$25,000	$16,000
Total Expenses	$84,208,000	$39,996,000	$31,668,000	$12,821,000
Other Income Expense	$-41,000	$141,000	$-4,000	$166,000
Other Non Operating Income Expenses	$-41,000	$141,000	$-4,000	$166,000
Net Non Operating Interest Income Expense	$6,638,000	$3,717,000	$49,000	$7,000
Interest Expense Non Operating	$2,000	$20,000	$25,000	$16,000
Operating Expense	$84,208,000	$39,996,000	$31,668,000	$12,821,000
General And Administrative Expense	$38,831,000	$10,057,000	$6,824,000	$3,952,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-77,611,000	$-36,144,000	$-31,632,000	$-12,648,000
Net Interest Income	$6,638,000	$3,717,000	$49,000	$7,000
Interest Income	$6,640,000	$3,737,000	$74,000	$23,000
Normalized Income	$-77,611,000	$-36,144,000	$-31,632,000	$-12,648,000
Net Income From Continuing And Discontinued Operation	$-77,611,000	$-36,144,000	$-31,632,000	$-12,648,000
Total Operating Income As Reported	$-84,208,000	$-39,996,000	$-31,668,000	$-12,821,000
Net Income Common Stockholders	$-77,611,000	$-36,144,000	$-31,632,000	$-12,648,000
Net Income	$-77,611,000	$-36,144,000	$-31,632,000	$-12,648,000
Net Income Including Noncontrolling Interests	$-77,611,000	$-36,144,000	$-31,632,000	$-12,648,000
Net Income Continuous Operations	$-77,611,000	$-36,144,000	$-31,632,000	$-12,648,000
Pretax Income	$-77,611,000	$-36,138,000	$-31,623,000	$-12,648,000
Interest Income Non Operating	$6,640,000	$3,737,000	$74,000	$23,000
Operating Income	$-84,208,000	$-39,996,000	$-31,668,000	$-12,821,000
Per Share
Diluted EPS	$-2.31	$-1.18	$-1.19	$-0.63
Basic EPS	$-2.31	$-1.18	$-1.19	$-0.63
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-77,145,000	$-35,669,000	$-31,199,000	$-12,434,000
Reconciled Depreciation	$464,000	$449,000	$399,000	$198,000
EBITDA (Bullshit earnings)	$-77,145,000	$-35,669,000	$-31,199,000	$-12,434,000
EBIT	$-77,609,000	$-36,118,000	$-31,598,000	$-12,632,000
Diluted Average Shares	$33,538,160	$30,538,378	$26,593,673	$19,976,596
Basic Average Shares	$33,538,160	$30,538,378	$26,593,673	$19,976,596
Diluted NI Availto Com Stockholders	$-77,611,000	$-36,144,000	$-31,632,000	$-12,648,000
Tax Provision	$0	$6,000	$9,000	$0
Research And Development	$45,377,000	$29,939,000	$24,844,000	$8,869,000
Selling General And Administration	$38,831,000	$10,057,000	$6,824,000	$3,952,000
Other Gand A	$38,831,000	$10,057,000	$6,824,000	$3,952,000

Fetched: 2026-07-08

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$765,570,000	$141,857,000	$87,134,000	$41,470,000
Total Assets	$780,556,000	$152,132,000	$94,642,000	$44,273,000
Total Non Current Assets	$286,284,000	$5,059,000	$4,702,000	$1,466,000
Non Current Prepaid Assets	$425,000	$130,000	$104,000	$88,000
Investmentin Financial Assets	$280,166,000	$0	-	-
Goodwill And Other Intangible Assets	$4,916,000	$3,964,000	$3,297,000	$31,000
Other Intangible Assets	$4,916,000	$3,964,000	$3,297,000	$31,000
Current Assets	$494,272,000	$147,073,000	$89,940,000	$42,807,000
Other Current Assets	$5,000	-	-	-
Prepaid Assets	$1,127,000	$1,330,000	$916,000	$699,000
Receivables	$718,000	$594,000	$867,000	$19,000
Other Receivables	$66,000	-	$818,000	-
Taxes Receivable	$18,000	$19,000	$31,000	$17,000
Accrued Interest Receivable	$634,000	$575,000	$0	-
Cash Cash Equivalents And Short Term Investments	$492,422,000	$145,149,000	$88,157,000	$42,089,000
Cash And Cash Equivalents	$352,932,000	$31,677,000	$88,157,000	$42,089,000
Cash Equivalents	$15,641,000	$0	-	-
Cash Financial	$337,291,000	$31,677,000	$88,157,000	$42,089,000
Other Non Current Assets	-	-	$62,000	-
Non Current Deferred Assets	-	-	-	$0
Debt
Total Debt	$429,000	$537,000	$886,000	$866,000
Long Term Debt And Capital Lease Obligation	$188,000	$261,000	$578,000	$668,000
Current Debt And Capital Lease Obligation	$241,000	$276,000	$308,000	$198,000
Liabilities
Total Liabilities Net Minority Interest	$10,070,000	$6,311,000	$4,211,000	$2,772,000
Total Non Current Liabilities Net Minority Interest	$188,000	$261,000	$578,000	$668,000
Current Liabilities	$9,882,000	$6,050,000	$3,633,000	$2,104,000
Other Current Liabilities	$599,000	$289,000	$149,000	$74,000
Payables And Accrued Expenses	$7,432,000	$4,782,000	$2,449,000	$1,450,000
Payables	$5,000	$13,000	-	-
Equity
Common Stock Equity	$770,486,000	$145,821,000	$90,431,000	$41,501,000
Total Equity Gross Minority Interest	$770,486,000	$145,821,000	$90,431,000	$41,501,000
Stockholders Equity	$770,486,000	$145,821,000	$90,431,000	$41,501,000
Gains Losses Not Affecting Retained Earnings	$-536,000	$-660,000	$-374,000	$-392,000
Retained Earnings	$-185,258,000	$-107,647,000	$-71,503,000	$-39,871,000
Preferred Securities Outside Stock Equity	-	-	-	$0
Other
Treasury Shares Number	$13,405	$31,253	$35,031	-
Ordinary Shares Number	$39,339,960	$31,826,549	$29,149,444	$24,898,908
Share Issued	$39,353,365	$31,857,802	$29,184,475	$24,898,908
Tangible Book Value	$765,570,000	$141,857,000	$87,134,000	$41,470,000
Invested Capital	$770,486,000	$145,821,000	$90,431,000	$41,501,000
Working Capital	$484,390,000	$141,023,000	$86,307,000	$40,703,000
Capital Lease Obligations	$429,000	$537,000	$886,000	$866,000
Total Capitalization	$770,486,000	$145,821,000	$90,431,000	$41,501,000
Additional Paid In Capital	$956,276,000	$254,125,000	$162,305,000	$81,761,000
Capital Stock	$4,000	$3,000	$3,000	$3,000
Common Stock	$4,000	$3,000	$3,000	$3,000
Long Term Capital Lease Obligation	$188,000	$261,000	$578,000	$668,000
Current Capital Lease Obligation	$241,000	$276,000	$308,000	$198,000
Pensionand Other Post Retirement Benefit Plans Current	$1,610,000	$703,000	$727,000	$382,000
Current Accrued Expenses	$7,427,000	$4,769,000	$2,449,000	$1,450,000
Dueto Related Parties Current	$5,000	$13,000	$0	$0
Investments And Advances	$280,166,000	$0	-	-
Held To Maturity Securities	$280,166,000	$0	-	-
Net PPE	$777,000	$965,000	$1,301,000	$1,347,000
Accumulated Depreciation	$-507,000	$-341,000	$-183,000	$-91,000
Gross PPE	$1,284,000	$1,306,000	$1,484,000	$1,438,000
Leases	$187,000	$187,000	$187,000	$187,000
Other Properties	$1,022,000	$1,044,000	$1,233,000	$1,228,000
Machinery Furniture Equipment	$75,000	$75,000	$64,000	$23,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$139,490,000	$113,472,000	$0	-
Duefrom Related Parties Current	-	$0	$18,000	$2,000
Construction In Progress	-	-	-	$31,000

Fetched: 2026-07-08

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-37,166,000	$-29,385,000	$-29,900,000	$-11,852,000
Operating Activities
Operating Cash Flow	$-36,988,000	$-29,234,000	$-29,837,000	$-11,458,000
Cash Flow From Continuing Operating Activities	$-36,988,000	$-29,234,000	$-29,837,000	$-11,458,000
Operating Gains Losses	-	-	-	-
Investing Activities
Capital Expenditure	$-178,000	$-151,000	$-63,000	$-394,000
Investing Cash Flow	$-305,107,000	$-110,572,000	$-63,000	$-394,000
Cash Flow From Continuing Investing Activities	$-305,107,000	$-110,572,000	$-63,000	$-394,000
Financing Activities
Issuance Of Capital Stock	$182,021,000	$42,236,000	$55,188,000	$37,990,000
Financing Cash Flow	$663,233,000	$83,595,000	$75,959,000	$36,963,000
Cash Flow From Continuing Financing Activities	$663,233,000	$83,595,000	$75,959,000	$36,963,000
Net Other Financing Charges	$370,374,000	$-368,000	$-1,230,000	$-1,030,000
Net Common Stock Issuance	$182,021,000	$42,236,000	$55,188,000	$37,990,000
Common Stock Issuance	$182,021,000	$42,236,000	$55,188,000	$37,990,000
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
Interest Paid Supplemental Data	$1,000	$0	$0	$16,000
Income Tax Paid Supplemental Data	$0	$6,000	$9,000	$0
End Cash Position	$352,932,000	$31,677,000	$88,157,000	$42,089,000
Beginning Cash Position	$31,677,000	$88,157,000	$42,089,000	$17,344,000
Effect Of Exchange Rate Changes	$117,000	$-269,000	$9,000	$-366,000
Changes In Cash	$321,138,000	$-56,211,000	$46,059,000	$25,111,000
Proceeds From Stock Option Exercised	$110,838,000	$41,727,000	$22,001,000	$3,000
Net Investment Purchase And Sale	$-304,929,000	$-110,421,000	$0	$0
Sale Of Investment	$147,065,000	$77,844,000	$0	$0
Purchase Of Investment	$-451,994,000	$-188,265,000	$0	$0
Net Intangibles Purchase And Sale	$0	$-35,000	$0	$0
Purchase Of Intangibles	$0	$-35,000	$0	$0
Net PPE Purchase And Sale	$-178,000	$-116,000	$-63,000	$-394,000
Purchase Of PPE	$-178,000	$-116,000	$-63,000	$-394,000
Change In Working Capital	$2,553,000	$1,133,000	$-2,427,000	$-491,000
Change In Other Current Liabilities	$-301,000	$-305,000	$-244,000	$-71,000
Change In Payables And Accrued Expense	$3,838,000	$2,476,000	$1,421,000	$332,000
Change In Accrued Expense	$3,846,000	$2,463,000	$1,421,000	$373,000
Change In Payable	$-8,000	$13,000	-	$-41,000
Change In Prepaid Assets	$-918,000	$-1,112,000	$-3,532,000	$-720,000
Change In Receivables	$-66,000	$74,000	$-72,000	$-32,000
Other Non Cash Items	$-1,313,000	$-3,610,000	-	-
Stock Based Compensation	$38,919,000	$8,987,000	$3,823,000	$1,483,000
Unrealized Gain Loss On Investment Securities	$0	$-49,000	$0	$0
Depreciation Amortization Depletion	$464,000	$449,000	$399,000	$198,000
Depreciation And Amortization	$464,000	$449,000	$399,000	$198,000
Amortization Cash Flow	$12,000	$4,000	$0	$0
Amortization Of Intangibles	$12,000	$4,000	$0	$0
Depreciation	$452,000	$445,000	$399,000	$198,000
Net Income From Continuing Operations	$-77,611,000	$-36,144,000	$-31,632,000	$-12,648,000
Sale Of PPE	-	-	$0	$0
Gain Loss On Sale Of PPE	-	-	$0	$0
Repayment Of Debt	-	-	-	$0
Issuance Of Debt	-	-	-	$0
Net Issuance Payments Of Debt	-	-	-	$0
Net Long Term Debt Issuance	-	-	-	$0
Long Term Debt Payments	-	-	-	$0
Long Term Debt Issuance	-	-	-	$0

Fetched: 2026-07-08